GlobeNewswire Inc. · Apr 18, 2024
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
Histogen has filed for voluntary Chapt. 11 protection to maximize share offering
HS
NASDAQ · HSTO
Histogen Inc.
Healthcare · Biotechnology
$0.02
Up+$0.00 (+0.00%)
Updated Aug 18, 2026, 6:25 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 85.44K
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 0
- Avg. volume
- 622
Price performance
HSTO price history
1M range · 0 trading sessions · Daily adjusted prices
HSTO does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest HSTO news
The latest Smart Investors Daily articles mentioning HSTO.
Stock researchCompany · Overview
HSTO research
Overview
Company profile and research snapshot.
Company profile
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 29, 2022 | HC Wainwright & Co. | Buy | — |
| Aug 30, 2021 | HC Wainwright & Co. | Buy | — |
| Jun 4, 2021 | Canaccord Genuity | Buy | — |
| Mar 4, 2021 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Sep 18, 2023
Histogen Announces Board Approval of Complete Liquidation and Dissolution
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of September.
GlobeNewswire Inc. · Jul 5, 2023
Histogen to Explore Strategic Alternatives
SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternatives with the intent to enhance shareholder value. Histogen has engaged Roth Capital Partners, LLC, to act as a strategic advisor in this process.
GlobeNewswire Inc. · May 11, 2023
Histogen Reports First Quarter 2023 Results and Provides Business Update
Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
